A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S

Exclusion Criteria

• •History of clinical malaria (any species).
• •Travel to a malaria endemic region during the study period or within the preceding six months with significant risk of malaria exposure.
• •Use of systemic antibiotics with known antimalarial activity within 30 days of CHMI (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones and azithromycin)
• •Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period.
• •Prior receipt of an investigational malaria vaccine or any other investigational vaccine likely to impact on interpretation of the trial data. If any volunteers in Group 1-4 undergo rechallenge, this exclusion criterion does not extend to the vaccines previously received in this trial
• •Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed).
• •Use of immunoglobulins or blood products within 3 months prior to enrolment.
• •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine (e.g. egg products, Kathon) or malaria infection.
• •Any history of anaphylaxis post vaccination.
• •History of clinically significant contact dermatitis.
• •History of sickle cell anaemia, sickle cell trait, thalassaemia or thalassaemia trait or any haematological condition that could affect susceptibility to malaria infection.
• •Pregnancy, lactation or intention to become pregnant during the study.
• •Use of medications known to cause prolongation of the QT interval and existing contraindication to the use of Malarone
• •Use of medications known to have a potentially clinically significant interaction with Riamet and Malarone
• •Any clinical condition known to prolong the QT interval
• •History of cardiac arrhythmia, including clinically relevant bradycardia
• •Disturbances of electrolyte balance, eg, hypokalaemia or hypomagnesaemia
• •Family history of congenital QT prolongation or sudden death
• •Contraindications to the use of all three proposed anti-malarial medications; Riamet, Malarone and Chloroquine.
• •History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
• •History of serious psychiatric condition that may affect participation in the study.
• •Any other serious chronic illness requiring hospital specialist supervision.
• •Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 standard UK units every week.
• •Suspected or known injecting drug abuse in the 5 years preceding enrolment.
• •Hepatitis B surface antigen (HBsAg) detected in serum.
• •Seropositive for hepatitis C virus (antibodies to HCV) at screening (unless has taken part in a prior hepatitis C vaccine study with confirmed negative HCV antibodies prior to participation in that study, and negative HCV RNA PCR at screening for this study).
• •An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system.59
• •Positive family history in 1st and 2nd degree relatives \<50 years old for cardiac disease.
• •Volunteers unable to be closely followed for social, geographic or psychological reasons.
• •Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination. In the event of abnormal test results, confirmatory repeat tests will be requested.
• •Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.